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Abstract
Adiponectin serum concentrations are an important biomarker in cardiovascular epidemiology with heritability etimates of
30–70%. However, known genetic variants in the adiponectin gene locus (ADIPOQ) account for only 2%–8% of its variance.
As transcription factors are thought to play an under-acknowledged role in carrying functional variants, we hypothesized
that genetic polymorphisms in genes coding for the main transcription factors for the ADIPOQ promoter influence
adiponectin levels. Single nucleotide polymorphisms (SNPs) at these genes were selected based on the haplotype block
structure and previously published evidence to be associated with adiponectin levels. We performed association analyses of
the 24 selected SNPs at forkhead box O1 (FOXO1), sterol-regulatory-element-binding transcription factor 1 (SREBF1), sirtuin 1
(SIRT1), peroxisome-proliferator-activated receptor gamma (PPARG) and transcription factor activating enhancer binding
protein 2 beta (TFAP2B) gene loci with adiponectin levels in three different European cohorts: SAPHIR (n = 1742), KORA F3
(n = 1636) and CoLaus (n = 5355). In each study population, the association of SNPs with adiponectin levels on log-scale was
tested using linear regression adjusted for age, sex and body mass index, applying both an additive and a recessive genetic
model. A pooled effect size was obtained by meta-analysis assuming a fixed effects model. We applied a significance
threshold of 0.0033 accounting for the multiple testing situation. A significant association was only found for variants within
SREBF1 applying an additive genetic model (smallest p-value for rs1889018 on log(adiponectin) = 0.002, b on original
scale =20.217 mg/ml), explaining ,0.4% of variation of adiponectin levels. Recessive genetic models or haplotype analyses
of the FOXO1, SREBF1, SIRT1, TFAPB2B genes or sex-stratified analyses did not reveal additional information on the regulation
of adiponectin levels. The role of genetic variations at the SREBF1 gene in regulating adiponectin needs further investigation
by functional studies.
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Introduction
Adipose tissue secretes a number of peptides referred to as
adipocytokines or adipokines [1]. One such adipocytokine is
adiponectin encoded by ADIPOQ (also known as APM1) which is
involved in regulation of insulin sensitivity, carbohydrate and lipid
metabolism, immunological responses, and cardiovascular func-
tions [2,3]. Several studies indicated that 39%–70% of the
variability in adiponectin levels is governed by genetic factors
[4–7]. During the last decade, several polymorphisms at the
ADIPOQ locus have been tested for association with adiponectin
levels [8,9]. Results of a meta-analysis and genome-wide
association (GWA) studies indicated a role of variants in the
ADIPOQ gene region in modulation of adiponectin levels [10,11].
Although this locus explains exceptionally high 2%–8% of the
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adiponectin levels [8,11,12], a major fraction of heritability is still
unexplained. The results of different GWA studies and linkage
analyses suggested that different genomic regions are likely to be
involved in regulation of adiponectin levels – either via a primary
influence or through pathways influencing body composition
[10,11,13–17].
The adiponectin gene promoter region contains binding sites for
various types of nuclear receptors (PPARG2, LRH, RXR),
transcription factors (CEBPA, SREBP1c, TFAP2B, FOXO1,
SP1) and at least three co-regulators of transcription factors
(SIRT1, NCOR1 and NCOR2) [18–20]. Kita et al. demonstrated
that the adiponectin promoter region from 2676 to +41 is
sufficient for promoter activity and that the region from 2676 to
2416 is crucial for basal promoter activity [21]. This region
consists of putative SREBP-responsive element (2676 to 2416)
and CEBP-responsive element (2416 to +41) which were both
required for promoter activity. Furthermore, it was shown that
FOXO1 up-regulates adiponectin gene transcription through a
FOXO1-response element in the adiponectin promoter containing
two adjacent FOXO1 binding sites [22]. SIRT1 increases
adiponectin transcription in adipocytes by activating FOXO1
and enhancing FOXO1 and CEBPA interaction. Low expression
of SIRT1 and FOXO1 can lead to impaired FOXO1-CEBPA
complex formation, which might contribute to the diminished
adiponectin expression in obesity [22]. PPARG2 may directly bind
to the human adiponectin promoter by forming heterodimers with
RXR and increase adiponectin promoter activity [18]. Moreover,
promoter activity of the adiponectin gene is inhibited by over-
expression of TFAP2B and enhanced by knockdown of its
endogenous expression [23].
These lines of evidence indicate that several transcription factors
and their co-regulators are involved in adiponectin gene expres-
sion: some through binding to the adiponectin promoter and
increasing promoter activity, others through negative regulation of
adiponectin gene expression. Taking this into consideration, we
hypothesized that genetic polymorphisms in these gene regions
may influence adiponectin gene transcription and adiponectin
levels. To evaluate this hypothesis, we performed association
analyses on the relation of selected polymorphisms in main
adiponectin transcription factors for adiponectin promoter with
the adiponectin levels in three different European cohorts.
Materials and Methods
Study Populations
SAPHIR Study. The SAPHIR study has been initiated in the
year 1999 as a population-based prospective study that investigates
genetic and environmental factors contributing to atherosclerotic
vascular diseases [8]. Study participants were recruited by a health
screening programs in large companies in and around the city of
Salzburg, Austria. The study comprises 1770 healthy unrelated
Caucasian subjects (663 females and 1107 males aged 39–67
years). At baseline, all participants were subjected to a compre-
hensive examination – detailed personal and family history,
physical, instrumental and laboratory investigations. Serum
adiponectin levels were measured by an enzyme-linked immuno-
sorbent assay kit from BioCat (Heidelberg, Germany). DNA was
available from 1760 participants and all relevant variables for
analyses were available for 1742 participants.
KORA F3 Study. The KORA F3 Study is the 10 year follow-
up of the third survey from the KORA-Study (Cooperative Health
Research in the Region of Augsburg), a population-based sample
from the general population of the South-German city of
Augsburg and surrounding counties from 1994/1995. The KORA
surveys have been described in detail previously [24]. Genome-
wide genotype data were available for a subsample of 1644
individuals with all relevant variables available for 1636 individ-
uals. Serum levels of adiponectin were measured by ELISA from
Mercodia (Uppsala, Sweden).
CoLaus Study. The CoLaus study is a single-center, cross-
sectional study which included 6188 Caucasian subjects aged 35 to
75 years from the city of Lausanne in Switzerland [25]. The major
goal of the CoLaus study is investigation of prevalence, severity
and molecular architecture of cardiovascular risk factors in a
Lausanne population. Recruitment began in June 2003 and ended
in May 2006. For 5435 participants, genome-wide genotype data
are available. The current analysis included 5355 extensively
phenotyped participants from this study. Plasma adiponectin levels
were measured using the ELISA assay from R&D Systems (MN,
USA).
Ethics Statement
All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki. Participants
from all 3 studies provided written informed consent and the
studies were approved by the local ethical committees (SAPHIR
Study, Ethical Committee of Land Salzburg; KORA F3, local
ethical committee of Bayerische Landesa¨rztekammer; CoLaus,
Institutional Ethic’s Committee of the University of Lausanne).
Selection of Transcription Factors
Three main transcription factors acting on the adiponectin
promoter (FOXO1, SREBP1c, TFAP2B) were selected based on
previously published data on their important role in regulation of
human adiponectin promoter activity or association of genetic
polymorphisms at these genes with adiponectin levels
[21,22,26,27]. CEBPA was excluded from our consideration
because of controversial data about the CEBPA binding site at the
adiponectin gene promoter or intron I [21,28,29] and lack of
evidence for a role of genetic variation at this locus in control of
adiponectin levels. One co-regulator of transcription factors
(SIRT1) was added based on its interaction with FOXO1 in
regulation of adiponectin expression [22].
SNP Selection
Genotype data of the main transcription factors (FOXO1,
SREBF1, TFAP2B) and one co-regulator of the transcription
factors (SIRT1) for adiponectin promoter were downloaded from
HapMap Data (Phase III/Rel.#2, Feb 09) (http://hapmap.ncbi.
nlm.nih.gov/cgi-perl/gbrowse/hapmap3r2_B36/). Then data
were transferred to SNP tagger (http://www.broad.mit.edu/
mpg/tagger/server.html) to identify haplotype-tagging SNPs.
Using the haplotype block structure we selected a maximally
informative subset of validated SNPs with minor allele frequency
of $5% and pairwise r2$80% (FOXO1 MAF=10%, r2 = 80%;
SREBF1 MAF=5%, r2 = 100%; TFAP2B MAF=5%, r2 = 80%;
SIRT1 MAF=5%, r2 = 80%). Haplotype frequencies in each gene
were estimated by implementation of the expectation maximiza-
tion algorithm. Four SNPs (rs2236319, rs3740051 at SIRT1,
rs987237 at TFAP2B and rs1801282 at PPARG) were included
additionally based on the previous publications [30–33].
Genotyping
Genomic DNA was isolated from whole blood in all three
populations according to manufacturer’s protocols. Genotyping in
SAPHIR cohort was performed using 5’ nuclease allelic discrim-
ination TaqMan genotyping method and pre-designed assays from
Genetics of Transcription Factors for Adiponectin
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Applied Biosystems (Foster City, CA, USA) according to the
manufacturer’s instructions.
After the SNPs have been genotyped in SAPHIR, in-silico
replication has been performed in the KORA F3 and CoLaus
cohorts. For both populations, imputed genome-wide genotypes
are available from which the respective SNPs were selected.
Original genotyping for KORA F3 and CoLaus studies were
performed using the Affymetrix GeneChip Human Mapping
500K Array Set (Affymetrix, Santa Clara, USA). Genotypes were
determined using the BRLMM clustering algorithm (Bayesian
Robust Linear Modeling using Mahalanobis distance, Affymetrix
500K Array Set) [34]. Imputation of genotypes was performed
with the software MACH v1.0.9 [35] in KORA F3 and IMPUTE
version 0.2.0 [36] in the CoLaus study.
Statistical Analysis
In each study population, the association of each SNP with log-
transformed adiponectin levels using linear regression models
adjusted for age, sex and body mass index (BMI) applying an
additive as well as recessive genetic model was analyzed. The
analyses were also conducted stratified for sex, in this case only
adjusting for age and BMI. A pooled effect size for all participants
as well as for men and women separately was obtained by meta-
analysis assuming a fixed effects model. The possibility of sex-
specific effects has been tested on each SNP using a t-test based on
the meta-analyzed effect estimates and standard errors on the
original scale of adiponectin [37].
Correction for multiple testing was applied on independent
number of tests for the main analyses (additive model). This
number was calculated using the effective number of loci [38],
which accounts for the correlation structure between the SNPs.
The percentage of explained variance per SNP and pair-wise
linkage disequilibrium (LD) between SNPs (D’ and R2) was
obtained using data from the SAPHIR study only. Also in
SAPHIR, haplotypes were estimated for all genes except PPARG
by the expectation maximization algorithm using the haplo.stats
package http://CRAN.R-project.org/package = haplo.stats) in
the R software environment [39]. Subsequent association analysis
of the number of haplotype copies on log-transformed adiponectin
was adjusted for age, sex and BMI.
Results
Patient and Genotype Characteristics
Clinical characteristics and adiponectin levels of the three study
populations are presented in Table 1. All three study populations
were comparable with respect to the phenotype studied and
adjusting variables with the exception of the higher mean age and
higher rate of type 2 diabetes (T2D) in the KORA F3 Study.
There was a higher frequency of male participants in the SAPHIR
population (62.7%) compared KORA F3 (49.5%) and CoLaus
cohorts (47.3%).
Initially, we genotyped 24 SNPs at FOXO1, SREBF1, PPARG,
TFAP2B and SIRT1 genes in SAPHIR cohort and added in-silico
replication of the respective SNPs using the imputed genotypes
from KORA F3 and CoLaus. Table 2 shows the corresponding
descriptive statistics of the genotypes. The minor allele frequencies
were comparable between all three populations. Issues regarding
the genotyping quality could only be detected in four SNPs. In
TFAP2B gene rs2143079 was poorly imputed (imputation quality
score RSQR,60% in both in KORA F3 and CoLaus) and
rs1569777 showed a deviation from the Hardy-Weinberg equilib-
rium in SAPHIR. Also in FOXO1, two SNPs (rs10507486 and
rs17446614) had a deviation from the Hardy-Weinberg equilib-
rium in SAPHIR cohort (Table 2).
Association Analysis
We evaluated the association of genetic variants in the main
transcription factors (FOXO1, SREBF1, PPARG, TFAP2B) and
their co-regulator (SIRT1) for ADIPOQ promoter with adiponectin
level. Meta-analysis of additive linear regression models adjusted
for age, sex, and BMI revealed association with log(adiponectin) in
all 5 selected SNPs in the SREBF1 gene. After calculating the
number of independent SNPs, which is 15 out of the 24 selected
SNPs, and correcting for multiple testing (a=0.05/15= 0.0033)
two SNPs from the SREBF1 gene remained significant: rs1889018
(p = 0.002) and rs2236513 (p = 0.003). Table 3 shows the results
for all three populations as well as the combined effects. For
rs1889018, for example, each copy of the minor allele leads to a
reduction of the adiponectin level of 0.217 mg/ml. This corre-
sponds to an explained variance of ,0.4% as calculated from the
SAPHIR Study. All selected SNPs within SREBF1 are highly
correlated (Figure 1).
Recessive effect models as well as haplotype analyses did not
provide any additional information (data not shown). There was
also no significant sex-specific effect in regulation of adiponectin
levels for SNPs in FOXO1, SREBF1, TFAP2B and SIRT1 genes.
Comparison of men-specific and women-specific data, however,
showed a sex-difference in rs1801282 (PPARG, p for sex-difference
= 0.012), though this cannot be deemed significant given the
number of tests involved. Nevertheless, it was interesting to see a
negative effect in men (b=20.235, p= 0.212), while the effect was
positive in women (b=0.288, p = 0.177).
Discussion
Considering that transcriptional control of the ADIPOQ is one of
the most important factors involved in regulation of adiponectin
levels, we hypothesized that genetic variation at the loci encoding
the main transcription factors controlling activity of the adipo-
nectin promoter might be involved in regulation of adiponectin
levels. We therefore performed association analyses of the 24
selected SNPs from 5 different transcription factors. We observed
a modest influence of genetic polymorphisms at the SREBF1 gene
on the adiponectin levels in three healthy West-Eurasian
populations including 8733 individuals, but not for the other
transcription factors (FOXO1, SIRT1, TFAP2B and PPARG). Two
of the five investigated polymorphisms (rs1889018 and rs2236513)
at the SREBF1 gene locus demonstrated an influence on the
adiponectin levels even after adjustment for multiple testing with
lower concentrations in carriers of the minor allele. Additionally,
Table 1. Clinical characteristics of the subjects from SAPHIR,
KORA F3 and CoLaus studies (means 6 SD or numbers (%)),
for whom all relevant variables and genotypes are available.
Parameters SAPHIR KORA F3 CoLaus
Number 1742 1636 5355
Male individuals 1092 (62.7%) 809 (49.5%) 2531 (47.3%)
Age (years) 51.466.0 62.5610.1 53.4611.0
BMI (kg/m2) 26.864.1 28.164.5 25.864.5
Adiponectin (mg/ml) 8.5864.58 10.6164.65 10.0568.00
Type 2 Diabetes (%) 58 (3.3%) 179 (10.9%) 348 (6.5%)
doi:10.1371/journal.pone.0052497.t001
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our data revealed a sex-specific effect of the Pro12Ala SNP at the
PPARG locus on adiponectin levels. The minor allele (Ala) of this
gene negatively correlated with adiponectin levels in men, but
positively in women. This finding was not significant after
correction for multiple testing.
In previous publications the role of genetic polymorphisms of
the transcription factors controlling ADIPOQ promoter activity in
regulation of adiponectin levels was not investigated in detail –
moreover the haplotype structure of these genes and sex-related
effects (with the exception of PPARG) were not taken into
consideration. Few years ago, Felder et al. using data from the
SAPHIR cohort and additionally 446 unrelated patients with T2D
discovered an association between one SNP at the SREBF1 gene
(rs2297508) and the prevalence of T2D and adiponectin levels
[26]. In our study we extended the analysis of genetic polymor-
phisms at the SREBF1 gene including additionally two cohorts and
4 SNPs, three of them having been selected as haplotype-tagging
SNPs and one (rs2236513) based on literature data [40]. In our
meta-analysis of 3 cohorts the two SNPs located in the 5’-UTR of
the gene showed the strongest association with adiponectin levels
(Figure 2). However, it should be noted, that all selected SNPs
within SREBF1 are highly correlated (Figure 1). Therefore, it can
be assumed that the different hits within this gene refer to the same
signal or signals. The search for the effect-triggering variants still
requires further investigation. The identified SNPs at the SREBF1
gene locus do not directly change its protein structure. They could,
however, change various aspects of mRNA metabolism such as
alterations of regulatory RNA-binding protein sites and mRNA
secondary structure, that may influence functional properties of
SREBP1c mRNA. It cannot be excluded that these SNPs are in
linkage disequilibrium with yet unidentified functional mutations,
either in the SREBF1 gene or a gene located in that region.
Table 2. Characteristics of the 24 SNPs in SAPHIR, KORA F3 and CoLaus, including genotype quality (call rate or imputation quality
RSQR).
Alleles SAPHIR (n=1760) KORA F3 (n =1644) CoLaus (n =5435)
SNP
Minor/
Major* MAF
Genotype
counts**
HWE
p***
Call
rate MAF
Genotype
counts**
HWE
p*** RSQR MAF
Genotype
counts**
HWE
p*** RSQR
FOXO1
rs10507486 A/G 0.203 1135/529/91 0.006 0.997 0.216 1016/546/82 0.424 0.999 0.194 3543/1673/219 0.206 1.000
rs17446593 G/A 0.178 1186/513/55 1.000 0.997 0.177 1111/483/50 0.866 0.905 0.168 3781/1478/174 0.027 0.943
rs17446614 A/G 0.155 1259/430/55 0.017 0.991 0.167 1144/451/49 0.594 1.000 0.153 3916/1378/141 0.155 1.000
rs2297627 G/A 0.304 867/710/180 0.055 0.998 0.310 788/692/164 0.526 1.000 0.309 2616/2280/539 0.179 1.000
rs2721068 C/T 0.260 958/666/121 0.709 0.991 0.258 902/636/106 0.699 0.963 0.254 3061/1982/391 0.005 0.977
PPARG
rs1801282 G/C 0.137 1309/413/35 0.688 0.998 0.143 1203/411/30 0.546 0.997 0.118 4248/1095/92 0.030 1.000
SIRT1
rs10823108 A/G 0.063 1546/203/9 0.414 0.999 0.074 1410/224/10 0.718 0.998 0.065 4757/649/29 0.176 0.998
rs12413112 A/G 0.120 1365/363/29 0.367 0.998 0.138 1220/395/29 0.755 0.996 0.124 4174/1174/87 0.850 0.996
rs1467568 A/G 0.340 769/768/209 0.424 0.992 0.362 679/739/226 0.286 0.998 0.336 2390/2433/611 0.759 0.997
rs2236319 G/A 0.063 1543/207/7 1.000 0.998 0.074 1412/222/10 0.716 0.999 0.065 4759/647/29 0.141 0.997
rs2273773 C/T 0.063 1544/205/8 0.683 0.998 0.074 1410/224/10 0.718 0.943 0.067 4738/667/30 0.176 0.972
rs3740051 G/A 0.063 1546/204/8 0.682 0.999 0.073 1413/221/10 0.589 0.999 0.065 4759/646/29 0.141 0.997
SREBF1
rs11656665 G/A 0.383 657/847/246 0.336 0.994 0.387 618/778/248 0.917 0.942 0.404 1939/2589/898 0.445 0.952
rs11868035 A/G 0.303 845/750/155 0.571 0.994 0.301 796/705/143 0.482 0.882 0.309 2582/2329/515 0.704 0.866
rs1889018 G/A 0.378 671/831/246 0.684 0.993 0.391 610/783/251 1.000 0.981 0.404 1948/2583/904 0.409 0.994
rs2236513 A/C 0.373 690/812/247 0.759 0.994 0.384 622/783/239 0.794 0.980 0.399 1987/2558/890 0.172 0.984
rs2297508 C/G 0.365 705/820/230 0.757 0.997 0.372 652/762/230 0.752 0.909 0.387 2054/2532/838 0.207 0.900
TFAP2B
rs1569777 T/C 0.117 1406/278/66 0.000 0.994 0.109 1307/315/22 0.526 0.936 0.126 4145/1208/81 0.393 0.957
rs2076309 T/C 0.432 555/885/316 0.264 0.998 0.450 504/802/338 0.584 0.988 0.455 1609/2702/1124 0.867 0.988
rs2143079 G/C 0.052 1578/179/2 0.231 0.999 0.063 1440/202/2 0.087 0.540 0.054 4865/553/16 1.000 0.574
rs2206277 T/C 0.202 1117/563/73 0.825 0.996 0.165 1147/451/46 0.858 0.922 0.149 3928/1388/118 1.000 0.957
rs2857506 A/G 0.117 1338/358/22 0.816 0.976 0.113 1294/330/20 1.000 0.949 0.105 4350/1025/60 0.881 0.974
rs7771651 T/A 0.145 1280/441/34 0.631 0.997 0.150 1185/424/35 0.772 0.992 0.161 3811/1497/127 0.212 0.985
rs987237 G/A 0.199 1123/571/64 0.454 0.999 0.164 1150/449/45 0.857 0.929 0.149 3933/1384/117 1.000 0.961
*Minor and Major alleles based on the plus-strand.
**Number of homozygotes for the major allele/heterozygotes/homozygotes for the rare allele; For KORA F3 and CoLaus, where imputed genotype scores have been
used, this are the numbers of the ‘‘best guess’’ genotypes (KORA F3) and rounded sum of genotype scores.
***Based on exact test of Hardy-Weinberg Equilibrium (HWE).
doi:10.1371/journal.pone.0052497.t002
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The PPARG2 is a ligand-activated transcription factor, which
acts as a heterodimer with the RXR [41,42]. PPARG2 has been
shown to increase transcription of the ADIPOQ gene and many
other genes that are involved in the pathogenesis of insulin
resistance [18,19,43]. Agonist-induced activation of PPARG is
known to cause adipocyte differentiation, improvement in insulin
sensitivity and also increased secretion of adiponectin by adipose
tissue [44,45]. The most frequently analysed and most well
documented SNP in the PPARG gene is a proline to alanine
substitution (Pro12Ala) in codon 12 of exon B (15% frequency
among Caucasians). This substitution has a protective effect
against the development of T2D. The Ala receptor variant is less
efficient in its ability to bind and trans-activate a PPARG2 target
gene in vitro [46]. The proline to alanine amino acid change also
might affect the secondary structure of the protein and its
functionality [47]. Heikkinen et al. (2009) suggested that the
Pro12Ala polymorphism might be involved in the function of G
protein, in sensitization of adiponectin signalling and altered
recruitment of cofactors [48].
Yamamoto et al. investigated the effect of the PPARG Pro12Ala
polymorphism on metabolic parameters and adiponectin levels in
598 Japanese people and found that adiponectin levels were
significantly lower in subjects with the Ala12 allele [33]. However,
a Finnish study demonstrated that adiponectin levels were
significantly higher among PPARG-Ala allele carriers after weight
loss induced by heavy exercises [32]. In our study, we could not
confirm an influence of the Pro12Ala polymorphism at the PPARG
gene on adiponectin levels. Nevertheless, sex-specific effects of this
SNP on adiponectin levels were observed indicating a positive
correlation in women and a negative in men. The mechanism
underlying this sex-specific effect of the PPARG gene in regulating
adiponectin levels and various metabolic traits is currently not
known. Sexual dimorphisms have frequently been reported in
relation to fat distribution and have been evidenced for genes that
affect BMI. Men are more likely to gain visceral fat and deep
subcutaneous fat than women [49–51]. Taking into consideration
that women have more subcutaneous fat as compared to men and
PPARG2 expression is more pronounced in subcutaneous adipose
tissue [52–54], one can speculate that sex-specific effects of this
polymorphism on adiponectin levels are related to differences in
fat distribution between men and women.
Our data did not reveal any effect of genetic polymorphisms at
the FOXO1, TFAP2B and SIRT1 gene loci on adiponectin levels.
This might be explained by their minor role in the process of
transcriptional regulation of the adiponectin gene or the investi-
gated polymorphisms do not have sufficient influence on the
structure of these transcription factor proteins.
Previous linkage studies suggested that different genetic
components might be involved in the regulation of adiponectin
levels, but their replications were inconsistent across different
ethnic populations [6,13,15–17,55–57]. Also the genetic variants
detected in GWA studies did not explain the high level of
heritability of adiponectin levels. The first GWA study was
conducted in a European population and showed strong
associations of adiponectin levels with ADIPOQ and CDH13 loci
[15]. Later, Richards et al. in a meta-analysis of three GWA
studies confirmed ADIPOQ and revealed a new locus - ARL15
(rs4311394) [58]. In 2010, Wu et al. provided a strong evidence of
association with adiponectin for three loci: ADIPOQ, CDH13 and
KNG1 together explained 7.5% and 8.9% of the variability of log-
transformed adiponectin levels in Filipino women and their
offspring, respectively. The strongest signal mapped to the
CDH13 and explained approximately 4% of the variability of
adiponectin levels [59]. The association of CDH13 locus with
adiponectin levels was later confirmed in another GWA studies
[14,60,61]. In a recent meta-analysis of GWA studies, 10 novel
loci for adiponectin levels were identified and confirming the
associations with variants at the ADIPOQ and CDH13 loci [10].
The genes included in our study were not detected in the
previously published GWA studies. Possible explanations for this
finding might be the different principles of SNP selection
(candidate gene approach in our study vs. use of common genetic
determinants across the genome in GWA studies) and the much
higher threshold for significance (p,1028) used in GWA studies.
Strengths and Limitations of the Study
The strength of our study is the selection of candidate genes
based on the known regulatory mechanisms of adiponectin gene
transcription. Additionally, we used the haplotype structure of the
candidate genes for SNP selection with the addition of previously
reported SNPs, allowing coverage of the whole gene region instead
of single SNPs in the gene region. Finally, we could show
direction-consistent significant effects for two SNPs in SREBF1
gene in three European populations, including a total number of
8733 participants.
Nevertheless, several limitations of this work should be noted.
The differences in mean age, proportion of male participants and
subjects with T2D between the three populations studied might
have influenced adiponectin levels [59,62]. Also we did not take
into consideration the genetic polymorphisms of all transcription
factors known to be important for the adiponectin promoter, but
included only four main transcription factors and one co-regulator
based which have been found to be of greatest importance in
regulation of adiponectin promoter activity and adiponectin levels.
Figure 1. Linkage disequilibrium structure across the SREBF1
single nucleotide polymorphisms. The pair wise linkage disequi-
librium (R2 and D’) is given for each pair of single nucleotide
polymorphisms. Color-coding is based on R2. The diagonal line indicates
the physical position of the single nucleotide polymorphisms relative to
each other.
doi:10.1371/journal.pone.0052497.g001
Genetics of Transcription Factors for Adiponectin
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e52497
Table 3. Linear model results on the 24 selected SNPs in the SAPHIR, KORA F3 and CoLaus study using an additive genetic model,
adjusted for age, sex and BMI, as well as the combined fixed effects meta-analysis results.
SAPHIR (n =1742) KORA F3 (n =1636) CoLaus (n=5355) Meta-analysis results
Meta-analysis results, separated for men
and women, t-test on difference
SNP ß (SE) P ß (SE) P ß (SE) P ß (SE) P ß (SE) men ß (SE) women P (diff)
FOXO1
rs10507486 0.23 (0.164) 0.23 20.169 (0.175) 0.62 20.075 (0.18) 0.70 0.007 (0.1) 0.80 0.003 (0.107) 20.007 (0.173) 0.96
rs17446593 20.161 (0.178) 0.28 0.006 (0.191) 0.60 0.07 (0.195) 0.89 20.036 (0.108) 0.98 20.009 (0.116) 20.047 (0.189) 0.84
rs17446614 20.092 (0.183) 0.56 20.123 (0.194) 0.87 20.026 (0.197) 0.99 20.081 (0.11) 0.90 0.031 (0.118) 20.208 (0.193) 0.21
rs2297627 0.037 (0.144) 0.56 20.136 (0.156) 0.61 20.099 (0.154) 0.35 20.06 (0.087) 0.40 20.003 (0.094) 20.129 (0.151) 0.40
rs2721068 20.167 (0.154) 0.51 20.046 (0.167) 0.82 20.073 (0.163) 0.48 20.099 (0.093) 0.46 0.009 (0.101) 20.211 (0.161) 0.17
PPARG
rs1801282 20.197 (0.195) 0.25 0.135 (0.21) 0.33 0.103 (0.22) 0.87 0.001 (0.12) 0.89 20.235 (0.129) 0.288 (0.208) 0.012
SIRT1
rs10823108 20.17 (0.277) 0.83 20.155 (0.276) 0.38 0.453 (0.288) 0.12 0.032 (0.162) 0.30 20.06 (0.169) 0.171 (0.291) 0.42
rs12413112 0.033 (0.206) 0.69 20.051 (0.212) 0.81 0.083 (0.217) 0.56 0.021 (0.122) 0.82 20.117 (0.13) 0.162 (0.216) 0.19
rs1467568 0.023 (0.142) 0.55 0.054 (0.149) 0.83 0.202 (0.152) 0.08 0.089 (0.085) 0.04 0.098 (0.091) 0.095 (0.149) 0.98
rs2236319 20.168 (0.279) 0.94 20.15 (0.277) 0.41 0.455 (0.288) 0.13 0.036 (0.162) 0.31 20.045 (0.171) 0.161 (0.291) 0.47
rs2273773 20.166 (0.278) 0.90 20.155 (0.276) 0.38 0.443 (0.288) 0.12 0.03 (0.162) 0.28 20.051 (0.17) 0.158 (0.291) 0.47
rs3740051 20.22 (0.278) 0.58 20.126 (0.277) 0.47 0.455 (0.288) 0.13 0.026 (0.162) 0.36 20.103 (0.17) 0.206 (0.29) 0.28
SREBF1
rs11656665 20.317 (0.141) 0.011 20.108 (0.149) 0.31 20.087 (0.15) 0.08 20.177 (0.085) 0.007 20.139 (0.091) 20.223 (0.148) 0.57
rs11868035 20.335 (0.149) 0.003 20.202 (0.160) 0.18 20.2 (0.167) 0.10 20.252 (0.091) 0.004 20.147 (0.098) 20.365 (0.161) 0.17
rs1889018 20.422 (0.141) 0.001 20.120 (0.149) 0.27 20.09 (0.146) 0.06 20.217 (0.084) 0.002 20.189 (0.089) 20.247 (0.147) 0.69
rs2236513 20.443 (0.140) 0.001 20.114 (0.150) 0.28 20.069 (0.147) 0.09 20.218 (0.084) 0.003 20.159 (0.09) 20.277 (0.147) 0.42
rs2297508 20.398 (0.141) 0.001 20.145 (0.150) 0.23 20.071 (0.154) 0.12 20.215 (0.086) 0.005 20.136 (0.092) 20.308 (0.15) 0.25
TFAP2B
rs1569777 0.134 (0.189) 0.48 0.379 (0.231) 0.13 0.234 (0.222) 0.72 0.233 (0.122) 0.66 0.077 (0.133) 0.379 (0.211) 0.15
rs2076309 0.023 (0.138) 0.76 20.185 (0.145) 0.20 20.083 (0.145) 0.64 20.079 (0.082) 0.34 20.043 (0.088) 20.132 (0.144) 0.54
rs2143079 0.363 (0.31) 0.13 20.632 (0.307) 0.03 20.445 (0.421) 0.11 20.204 (0.193) 0.08 20.088 (0.212) 20.405 (0.334) 0.34
rs2206277 20.087 (0.169) 0.93 0.409 (0.197) 0.11 0.093 (0.206) 0.54 0.115 (0.109) 0.28 0.082 (0.116) 0.212 (0.193) 0.50
rs2857506 20.055 (0.213) 0.94 20.207 (0.231) 0.38 20.085 (0.236) 0.43 20.113 (0.131) 0.64 20.119 (0.139) 20.098 (0.231) 0.93
rs7771651 0.008 (0.194) 0.97 20.167 (0.205) 0.90 20.061 (0.199) 0.76 20.07 (0.115) 0.74 20.018 (0.139) 20.162 (0.203) 0.48
rs987237 20.051 (0.172) 0.85 0.431 (0.197) 0.09 0.094 (0.206) 0.53 0.139 (0.11) 0.23 0.085 (0.116) 0.263 (0.195) 0.36
Effect estimates and standard errors (for the combined as well as sex-specific analyses) are based on the original adiponectin scale, whereas p-values are taken from the
linear regression on log(adiponectin).
doi:10.1371/journal.pone.0052497.t003
Figure 2. Schematic structure of SREBF1 gene. Exons are numbered indicating the alternatively spliced -a and -c variants. Genomic location of
the analyzed single nucleotide polymorphisms are marked. The single nucleotide polymorphisms highlighted in yellow showed a strongly associated
with adiponectin levels in our study. The single nucleotide polymorphism highlighted in grey showed a significant association in a previous study [26]
and was only borderline significantly associated in the present study (p = 0.004).
doi:10.1371/journal.pone.0052497.g002
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Finally, the study size was too small to performed analyses
stratified for T2D or obesity.
Conclusion
From the 24 selected SNPs at the five investigated transcription
factors important for regulation of the adiponectin gene promoter,
only those at the SREBF1 gene had a modest influence on
adiponectin levels in three healthy West-Eurasian populations.
The role of genetic variations at the SREBF1 gene and possible
sex-related effects of PPARG in regulation of adiponectin levels
have to be investigated in functional studies. Understanding the
genetic mechanisms regulating adiponectin levels will expand our
present knowledge concerning the factors that influence adipo-
nectin levels. This could also lead to new therapeutic strategies to
normalize circulating levels of adiponectin in subjects with
metabolic disorders and cardiovascular disease.
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